AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04915482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined use of TPO-RAs with low-dose anti-CD20 antibody
Description: Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
Study NCT04915482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The best available therapy
Description: The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
Study NCT02826837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
Description: The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)
Study NCT05487118 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT + MCE
Description: Placebo PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, without any emission of therapeutic dose. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
Study NCT05022472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Individual Awareness and Education.
Description: The 2VIDA! working group has developed culturally competent COVID-19 educational and outreach materials (available printed and electronically) in English and Spanish that are written at the 8th grade level (the average reading level of adults in the United States) that peer-health educators will distributed to community members during their visits to the participating SYH community centers, door-to-door, local supermarkets, and CBO's in the selected communities. These materials have general information on COVID-19 as well as educational information and resources regarding COVID-19 prevention, symptoms, testing, contact tracing, COVID-19 vaccine (how it works, technology used, administration \[2-dose series and importance of vaccine completion\]), safety concerns, benefits, dispelling common misconceptions and misinformation, and other topics identified based on community needs. This information will be updated monthly to ensure the most up to date information.
Study NCT05022472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Community Outreach & Health Promotion.
Description: Peer-health educators will work with local CBO's and facilitate a combination of live broadcast sessions, pre-recorded webinars, social media posts, and other outreach activities in English and Spanish reaching community members with information on the above COVID-19 related topics as well as other identified needs such as what to do if a family member is infected and where you can get the COVID-19 vaccine. The goal is to reach 10,000 viewers (per session) in the various social media platforms in the three randomly selected communities.
Study NCT05022472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Individual Health Education & Linkages to Medical and Supportive Services.
Description: SYHealth will establish a COVID-19 Resource Center within the participating health centers in the three randomly selected communities (intervention sites only) providing individual COVID-19 related health education and linkages to medical and supportive services for patients and community members in need of additional education and support regarding COVID-19 disease and COVID-19 vaccine.
Study NCT05022472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pop-up community vaccination sites
Description: We will offer the COVID-19 vaccine at the participating SYHealth community health centers and pop-up vaccination stations that will be set-up in these communities (intervention sites) as part of the interventions efforts to increase access and uptake of the COVID-19 vaccine. We have identified various open spaces (e.g., public parks) in these communities to set-up the vaccination stations. Additionally, data will be collected to assess individual, social, and contextual factors related to access, acceptance, and uptake of the COVID-19 vaccine.The survey will last approximately 10-15 minutes and will be self-administered in both English and Spanish. Following the survey participants will be offered the COVID-19 vaccine and will be made an automatic appointment for the 2nd dose (4-week follow-up) and will be asked to complete a 5 min survey during the follow-up visit.
Study NCT05487118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBMT + MCE
Description: Active PBMT will be irradiated at 4 sites in the lumbar region and 6 sites in the patient's abdominal region, with a dose of 30 J per site. After, the patient will be submitted to a MCE protocol consisting on stabilization exercises and isometric abdominal training. The treatment will be performed twice a week (on non-consecutive days), for 6 weeks, yielding 12 treatment sessions.
Study NCT06440642 — intervention group
Intervention type: DEVICE
Intervention: tonopen
Description: Intraoculer pressure will be measured in the supine position after intubation (T1), during pneumoperitoneum (T2), when placed in steep trendelenburg posıtıon (T3), at the end of the operation when pneumoperitoneum is terminated (T4), after being placed back in the supine position (T5), and 10 minutes after being placed back in the supine position (T6).
Study NCT05721560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair with the SINEFIX
Description: Treatment of rotator cuff lesions of size up to 2 cm using the SINEFIX implant and instruments
Study NCT05924126 — intervention group
Intervention type: OTHER
Intervention: empiric antibiotic therapy
Description: septic ICU patient given broad spectrum antibiotic therapy
Study NCT04801641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six placebo capsules taken orally twice daily
Study NCT04801641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Titrated to two 0.5 mg capsules and four placebo capsules taken orally twice daily (Low-Dose) OR Titrated to six 0.5 mg capsules taken orally twice daily (High-Dose)
Study NCT05543824 — intervention group
Intervention type: DRUG
Intervention: Levobupivacaine
Description: Patients who require placement of an epidural catheter to control postoperative pain and invasive blood pressure will be identified, allowing advanced monitoring using the MostCare Up® device. After identification, the objective of the study will be explained and their consent will be requested to collect the data after the intervention, recording the hemodynamic data before and after the initial bolus of local anesthetic administered: 0.25% levobupivacaine, the dose of which is calculated with the Takasaki formula: 0.05ml x weight (kg) x number of dermatomes to anesthetize
Study NCT04988321 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged continuous theta burst stimulation (pcTBS)
Description: Non-invasive brain stimulation (transcranial magnetic stimulation or TMS) which consists of a stimulating coil being held over the head. When this coil delivers a painless magnetic pulse, it feels like a quick, light tap on the head. Two different coils will be used to perform TMS. One coil will be used to determine stimulation parameters for the pcTBS protocol. The second coil will be used to implement pcTBS, which is a repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on the head. Participants will receive two procedures during one session, one with active stimulation and one with inactive stimulation.
Study NCT04770298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Halliwick Concept
Description: Halliwick Concept: Water intervention Bobath Concept: Neurodevelopmental Treatment
Study NCT06033690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary guide
Description: use of the food guide for education, clarification of doubts
Study NCT06297954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Patients will receive metoclopramide 20 mg IV in a single dose prior to randomization.
Study NCT05021172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT05021172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive Passport to Health booklet
Study NCT05021172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete ePrognosis
Study NCT06297954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo 10 ml IV in a single dose prior to randomization.
Study NCT05021172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04511936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-Lumen AMD
Description: Microcurrent stimulator
Study NCT04511936 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: i-Lumen AMD Sham
Description: Sham microcurrent stimulator
Study NCT06153914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sequential Adult Left Lateral Liver Transplantation
Description: Hemihepatectomy combined with orthotopic left lateral lobe liver transplantation is performed first, and residual liver resection is performed after the graft has grown to a sufficient functional liver volume. After the two-stage surgery, we will follow up on all subjects for one year.
Study NCT05307068 — intervention group
Intervention type: OTHER
Intervention: No intervention was applied to the groups the samples will be collected in terms of the diagnosis ( periodontitis, healthy)
Description: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
Study NCT04386252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-COVID-19
Description: Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
Study NCT05416593 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General exercise prescription (FITT)
Description: The (1) control group (FITT) will receive a preexercise evaluation and 3 individualized training sessions based on the ACSM and FITT principles (ACSM, 2021). These are the procedures commonly used for apparently healthy individuals that start to exercise in health clubs.
Study NCT05416593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective regulation (AFFECT)
Description: As for the (2) experimental group (AFFECT), the focus will be given to exercise intensity assessment and manipulation. The same preexercise evaluation, number of individualized sessions, and methodological approach (i.e., FITT) will be made. However, individual preferences and experiences regarding exercise intensity will be assessed in the preexercise evaluation. These will be used to select the exercise sessions' initial intensity. Moreover, intensity self-selection guidance and affective response assessments will be made throughout the session for continuous intensity adjustments (aiming for pleasurable feelings).
Study NCT04523701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: white test (= the administration of SMOFlipid retrograde through the cystic duct)
Description: white test (= the administration of SMOFlipid retrograde through the cystic duct)
Study NCT06102616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: measure Osteocalcin level
Description: in gingival crevicular fluid before and during orthodontic tooth movement
Study NCT05166070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD133
Description: The enhanced MSLN-CAR-T cell design of this study is obtained by co-infecting T cells with two lentiviral vectors. One lentiviral vector expresses CD19-CAR and tEGFR molecular safety switch, and the other lentiviral vector expresses MSLN- CAR and dnTGFβRII receptors. dnTGFβRII receptor without intracellular signal is used to resist the inhibition of T cell function by the immune microenvironment of tumor tissue. In addition, for the safety of CAR-T cell application in vivo, tEGFR is used in the CAR design as a molecular safety switch for CAR-T cells.
Study NCT06499766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biodiversity intervention by inactivated microbial extract
Description: Participants use the lotion including microbial extract on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
Study NCT06499766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention by colored lotion
Description: Participants use the lotion including safe, non-active coloring ingredient on one arm twice a day for 28 days. No other lotions or creams are used simultaneously on this area. Atopy medicines are not used during the trial or 14 days before the trial.
Study NCT06521541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation program
Description: Patients adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.Patients were evaluated for changes during neoadjuvant therapy and postoperative recovery
Study NCT06521541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERAS program
Description: The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.
Study NCT05606484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise with non-immersive virtual reality
Description: Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
Study NCT05606484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with non-immersive virtual reality
Description: Patients will exercise for 30 minutes with non-immersive virtual reality (VR) with a perceived exertion between 12-15 (somewhat hard-hard) on the Borg scale. Patients will perform 3 weekly sessions during the second hour of hemodialysis, on simultaneous days.
Study NCT05606484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise with a static pedal
Description: Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
Study NCT05606484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with a static pedal
Description: Patients will exercise with a stationary pedal for 30 minutes at an intensity of 12-15 (somewhat hard-hard) on the Borg scale of perceived exertion. The patients will carry out an exercise session 3 times a week on alternate days, coinciding with the patients of the exercise with VR.
Study NCT05048758 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05298813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBIO123
Description: IBIO123 1 mg, 5 mg and 10 mg
Study NCT05298813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT04185636 — intervention group
Intervention type: DEVICE
Intervention: MolecuLight i:X imaging
Description: The MolecuLight i:X Imaging Device will be used to take standard (ST) and fluorescent (FL) images of each graft site. The MolecuLight i:X will also be used to take measurements of the wound using the measurement feature of the device.
Study NCT06404723 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrinogen to albumin Ratio and C-reactive to Albumin Ratio
Description: to detect their relation to disease activity to use as predective and prognostic tools
Study NCT05829395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: metaverse- based education
Description: The nursing process course will be conducted in a metaverse environment. A virtual classroom is designed in the metaverse space for the execution of this course.~Starting from the week following the pre-test application, online training will continue according to the Metaverse-based for a total of 3 weeks, two hours a week, for the intervention group. At the end of the 3 weeks, the Instructional Materials Motivation Scale and Academic Success Assessment (Quiz) will be re-administered as a post-test.
Study NCT05693103 — intervention group
Intervention type: DEVICE
Intervention: High-Intensity Focused Electromagnetic therapy
Description: The HPM-6000UF is a non-invasive therapeutic device. The device produces electromagnetic field that interacts with the tissues of the human body.~The electromagnetic field delivered in the muscular or neuronal tissue area is triggering the stimulation and tonisation.
Study NCT05730127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conditioning stimulus
Description: Pain stimulus on non-dominant side
Study NCT05730127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioning stimulus
Description: Pain stimulus on non-dominant side
Study NCT04773847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.
Description: Surgical reconstruction of maxillofacial osseous defect with MimetikOss 3D.
Study NCT04851743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: The experimental extremity will received a single treatment session of TrP dry needling as follows: the therapist will located the TrP and will applied manual compression until the participant will reported pain. After that, dry needling technique will be performed on the TrPs for 60 seconds.
Study NCT04948060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced lung cancer screening services
Description: A theoretically sound and evidence-based, multi-component implementation strategy will be applied which includes care quality benchmarking and regular performance feedback, academic detailing provided by specially trained primary care clinicians, practice facilitation provided by trained and certified Practice Facilitators (PFs), health information technology (HIT) support, and facilitated professional networking to promote the cross-pollination and rapid dissemination of solutions and best practices in primary care settings
Study NCT06046794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analyze of GemCore status
Description: Genomic analyze of GemCore status
Study NCT05225376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity sessions for pregnant women
Description: The physical activity sessions will take place once a week at the Estaing UHC, in the room used for the childbirth and parenting preparation classes of the outpatient obstetrics-gynecology clinic; and twice a week on Zoom. These sessions will be supervised by an APA professional (degree in STAPS and APA).~The measurement of the women's physical conditions will make it possible to adapt and individualize the PA sessions to each woman's level.
Study NCT06262204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hallux Valgus Treatment with Shark Screw®
Description: This is a prospective, randomised study in which hallux valgus is corrected by means of a chevron/kin surgery technique using metal screws or human allogenic cortical bone screws (Shark Screw®, Surgebright, Lichtenberg, Austria). X-rays are taken before the operation at 6 weeks, three, six and twelve months after the operation. The X-ray images provide information on whether bony degeneration has taken place. In addition, the American Orthopaedic Foot \& Ankle Society (AOFAS) hallux score, FFI score, hallux valgus angle (HVA) and intermetatarsal angle (IMA) are determined. These data are collected preoperatively and 4 weeks (HVA and IMA), six and twelve months postoperatively in order to rule out a change in the HVA and IMA and to document the changes in the AOFAS/FFI.